In biotech, the first barrier is rarely the science. It is the moment a young founder tries to translate science into a decision that other people can fund. The slide deck can be polished, the mechanism of action can be sound, the unmet need can be clear. Then the questions start coming from the other side of the table: What is the path through regulation? What is the real risk? What is the plan when the first trial result is messy?
Mentorship, in that moment, is not inspiration. It is operational support.
Leen Kawas has built a career that sits directly on that fault line between discovery and execution. She is CEO of EIT Pharma, sits on the board of Inherent Biosciences, and serves as co-founder and managing general partner of Propel Bio Partners, a biotech-focused venture firm. Her bio materials emphasize that she came to the United States in 2008, then helped build and lead a company through late-stage clinical work and an IPO, raising over $400 million along the way.
That combination shapes how she mentors. She is not mentoring from the sidelines of the industry. She is mentoring from inside the machinery that determines who gets resourced and who does not.
Mentorship as a system, not a favor
Kawas’s own public profiles describe her as a supporter of scientist entrepreneurs, with special emphasis on women, and as a member of the Springboard Network, a community built to help women-led companies scale. That matters because many mentorship narratives stop at individual advice. Her approach looks more like building an enabling environment around a founder.
The most valuable mentorship in biotech tends to come in the form of systems:
- Introducing founders to people who can unlock the next stage, including operators, capital partners, scientific advisors, and talent.
- Teaching the founder how decisions get made, including what investors are listening for and what they are quietly concerned about.
- Helping the founder design a process that can survive ambiguity, since biology rarely delivers clean story arcs.
The board work of Leen Kawas reinforces this orientation toward structure. Inherent Biosciences describes her as drawing on experience across drug discovery, clinical trial methodology, regulatory strategy, commercialization, and financing, and as a “passionate supporter” of women scientist entrepreneurs. Those domains are the pressure points where early founders often get stuck, not from lack of intelligence, but from lack of navigational support.
The difference between mentoring and sponsoring
Many women in biotech can find advice. Fewer can find sponsorship, the kind that changes who gets included in the room.
Kawas’s mentorship footprint shows up through networks designed for that role. Her Inherent bio notes her involvement with Springboard, plus membership in Chief, a private network for women executives focused on peer support and leadership development. It also notes her advisory role with Nucleate, a student-led biotech nonprofit that supports emerging teams.
This is what sponsorship looks like in practice: helping women gain proximity to deal flow, governance conversations, and leadership peers, then staying close enough to their decisions that momentum does not stall after a single introduction.
She mentors by teaching founders to ask better questions
A recurring theme in Kawas’s published descriptions of her work is that she evaluates and supports companies through a cross-disciplinary lens: science, operations, finance, and strategy. Mentorship in this mode often sounds like questions, asked early enough to change outcomes:
What is the minimum clinical result that would change the company’s trajectory?
Which risks are real, and which risks are presentation problems?
Where is the company over-building, and where is it under-investing?
Those questions do more than refine a pitch. They teach a founder how to think like a CEO who must allocate scarce resources under uncertainty. It is a quiet transfer of executive pattern recognition, which is one of the rarest assets in early-stage life science.
Mentorship anchored in community responsibility
Kawas’s mentoring is not positioned as private coaching only. Her bios consistently connect her leadership to community engagement, including board service with Life Science Washington and Alzheimer’s-focused organizations. Life Science Washington’s own announcement of new directors lists Kawas among elected directors, placing her inside a regional ecosystem where founders, investors, and operators intersect.
That matters because leadership pipelines are often local before they are national. Mentorship is easier to sustain when it is embedded in an ecosystem with recurring events, repeat interactions, and shared norms about who gets supported.
A Women In Bio event listing for Los Angeles describes Kawas as a Springboard participant and a passionate supporter of women scientist entrepreneurs, and frames her current work as supporting “next-gen innovators.” That is not just personal branding. It is a signal that she treats mentorship as part of her operating job, not a side activity.
What her model offers the next generation
If you step back from the roles and organizations, a clear mentorship philosophy emerges.
First, she normalizes ambition. Her own trajectory, from scientist to executive to investor, demonstrates that leadership paths can be built intentionally, even in fields that often reward conventional profiles.
Second, she makes the invisible visible. Through networks like Springboard and through advisory work that spans fundraising, governance, and clinical strategy, she helps founders see the rules of the game early enough to play it well.
Third, she mentors with leverage. Capital is one form of leverage. Introductions are another. Process design is another. Her position at a venture firm that explicitly frames her mission as supporting impactful research and emerging innovators means her mentorship can be expressed through resourcing, not only reassurance.
The quiet goal: durable women leaders
The best mentorship does not produce a single successful pitch. It produces a leader who can keep making decisions after the pitch, when the data gets complicated and the timeline stretches.
Leen Kawas’s mentoring model, as reflected in her board roles, network affiliations, and investor identity, is built for that reality. She mentors by building scaffolding around talent: structured communities, real governance exposure, and decision-making frameworks that survive uncertainty.
That is how the next generation of women leaders gets built in biotech: not through one-off encouragement, but through sustained access to the mechanisms that turn scientific potential into durable companies.
Check out Kawas’s profile on crunchbase.com for more.